Literature DB >> 23465357

Does the devil facial tumour produce immunosuppressive cytokines as an immune evasion strategy?

Katrina Morris1, Katherine Belov.   

Abstract

A unique transmissible cancer known as the Devil Facial Tumour Disease (DFTD) is threatening the Tasmanian devil (Sarcophilus harrisii) with extinction. This disease is highly unusual as it is one of only two naturally occurring contagious cancers. The tumour is transmitted by biting and is able to spread between genetically diverse hosts. Why the tumours are not recognised as foreign and rejected by the host immune system in unknown. One mechanism that allows human cancers to avoid immune suppression is by producing cytokines which down-regulate the hosts immune system. Four key cytokines involved in this process are TGFβ1, VEGF-A, IL-10 and IL-6. In this study we investigated whether these cytokines could be involved in immune avoidance in DFTD. To do this we compared expression of these cytokines in tumour and control tissues using qPCR. We found no significant upregulation of any of these cytokines in tumour tissue. We therefore conclude that these cytokines do not play a role in the spread of DFTD. Further work will be needed to elucidate how DFTD cells avoid immune rejection. Crown
Copyright © 2013. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23465357     DOI: 10.1016/j.vetimm.2013.02.008

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  8 in total

Review 1.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

2.  Two Decades of the Impact of Tasmanian Devil Facial Tumor Disease.

Authors:  Gregory M Woods; Samantha Fox; Andrew S Flies; Cesar D Tovar; Menna Jones; Rodrigo Hamede; David Pemberton; A Bruce Lyons; Silvana S Bettiol
Journal:  Integr Comp Biol       Date:  2018-12-01       Impact factor: 3.326

Review 3.  Lessons learnt from the Tasmanian devil facial tumour regarding immune function in cancer.

Authors:  Emma Peel; Katherine Belov
Journal:  Mamm Genome       Date:  2018-09-17       Impact factor: 2.957

4.  Identification, characterisation and expression analysis of natural killer receptor genes in Chlamydia pecorum infected koalas (Phascolarctos cinereus).

Authors:  Katrina M Morris; Marina Mathew; Courtney Waugh; Beata Ujvari; Peter Timms; Adam Polkinghorne; Katherine Belov
Journal:  BMC Genomics       Date:  2015-10-15       Impact factor: 3.969

5.  Immunology of naturally transmissible tumours.

Authors:  Hannah V Siddle; Jim Kaufman
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

6.  Significant decline in anticancer immune capacity during puberty in the Tasmanian devil.

Authors:  Yuanyuan Cheng; Kim Heasman; Sarah Peck; Emma Peel; Rebecca M Gooley; Anthony T Papenfuss; Carolyn J Hogg; Katherine Belov
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

7.  Tasmanian devils with contagious cancer exhibit a constricted T-cell repertoire diversity.

Authors:  Yuanyuan Cheng; Mariano Makara; Emma Peel; Samantha Fox; Anthony T Papenfuss; Katherine Belov
Journal:  Commun Biol       Date:  2019-03-13

8.  Identification and analysis of divergent immune gene families within the Tasmanian devil genome.

Authors:  Katrina M Morris; Yuanyuan Cheng; Wesley Warren; Anthony T Papenfuss; Katherine Belov
Journal:  BMC Genomics       Date:  2015-11-26       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.